《新股消息》悠可集團通過上市聆訊 傳集資4億至6億美元
內地美妝品牌電商悠可集團已通過聯交所上市聆訊,由中信証券及瑞信擔任聯席保薦人。早前有外電消息指,悠可集團計劃於本次香港IPO中集資4億至6億美元。
聆訊後招股資料顯示,悠可集團於去年底擁有涵蓋44個品牌合作夥伴的組合,當中包括Clarins、L’OCCITANE等33個品牌賦能合作夥伴及Penhaligon’s等11個孵化品牌合作夥伴。集團透過向品牌提供孵化服務,從而收取服務費,並透過經銷模式,將美妝產品出售予京東(09618.HK)、唯品會(VIPS.US)等電商平台,產生銷售收益。
悠可集團於上市前引入多名投資者,包括騰訊(00700.HK)前副總裁彭志堅創立的元生資本、中國平安(02318.HK)、金鎰資本及嗶哩嗶哩(09626.HK)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.